ClaimEli Lilly's combination of Zepbound and eloralintide demonstrated 23% weight loss in a Phase 2 trial for people with obesity.

ClaimBoehringer Ingelheim's survodutide demonstrated significant body weight reduction and improved glycemic control in adults with obesity or overweight and type 2 diabetes in the Phase III SYNCHRONIZE-2 trial.

ClaimMerck's investigational anti-TL1A monoclonal antibody, tulisokibart, met its primary and key secondary endpoints in a Phase 2b study for moderate to severe hidradenitis suppurativa, demonstrating superiority over placebo.

Claim60 Degrees Pharmaceuticals will disclose interim analysis results from its clinical study evaluating tafenoquine in patients hospitalized with severe babesiosis on October 6, 2026.

ClaimSurvodutide demonstrated significant body weight reduction and improved glycemic control in adults with obesity or overweight and type 2 diabetes in the Phase III SYNCHRONIZE-2 trial.

ClaimRoche announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine.

ClaimThe Phase 2 COURAGE trial demonstrated that trevogrumab significantly preserved lean mass and muscle volume in patients undergoing GLP-1 receptor agonist-induced weight loss.

ClaimBristol Myers Squibb reported liver injury events, including one death, in its Phase 3 ALOFT program for admilparant, leading to a protocol amendment and raising concerns about the LPA1-R inhibitor class.

ClaimFoghorn Therapeutics and Lilly have decided to discontinue the development of FHD-909 and the Selective SMARCA2 degrader program due to insufficient efficacy observed in the Phase 1 clinical trial.

ClaimUbamatamab demonstrated a 73% objective response rate and 11-month median progression-free survival in heavily pre-treated low-grade serous ovarian cancer patients in an initial Phase 1/2 study.

ClaimMerck & Co (MSD) announced that its investigational humanised monoclonal antibody, tulisokibart, achieved its primary endpoint in the Phase IIb MK-7240-012 study for moderate to severe hidradenitis suppurativa.

ClaimEli Lilly's investigational therapy orforglipron demonstrated superior reductions in body weight and A1C levels compared to oral semaglutide in an indirect treatment comparison of data from the ACHIEVE-3 and PIONEER PLUS studies.

ClaimAnalysis of the REDEFINE-1 study presented at EASD 2026 showed that CagriSema achieved substantial and sustained weight loss at week 68 across all participant groups.

ClaimBristol Myers Squibb revised its Phase 3 trial for admilparant to increase liver safety monitoring following reported liver-related side effects and a patient death.

ClaimResults from Zealand Pharma's Phase 2 ZUPREME-1 trial for petrelintide, published in The Lancet Diabetes & Endocrinology, demonstrated clinically meaningful double-digit weight loss and significant improvements in cardiometabolic risk factors with a gastrointestinal tolerability profile comparable to placebo.

ClaimEupraxia Pharmaceuticals' EP-104GI demonstrated durable symptom responses, high clinical remission rates, and a favorable safety profile out to 52 weeks in the Phase 1b/2a RESOLVE trial for Eosinophilic Esophagitis.

ClaimInvivyd's VYD2311 demonstrated superior safety and tolerability compared to an mRNA-based COVID-19 vaccine in the Phase 3 LIBERTY study, with plans for a Biologics License Application submission via the Accelerated Approval Program.

ClaimVectorY Therapeutics has expanded its global Phase I/II PIONEER-ALS clinical trial for VTx-002 in amyotrophic lateral sclerosis from 12 to 36 participants to generate a broader clinical dataset.

ClaimRoche has discontinued the development of its anti-myostatin therapy, emugrobart, for obesity following a disappointing interim analysis of its Phase 2 GYMINDA trial.

ClaimVasomune Therapeutics has completed patient enrollment for its AV001-004 Phase IIa trial evaluating Pegevongitide (AV-001) in hospitalized pneumonia patients requiring supplemental oxygen.

ClaimMoleculin Biotech has completed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in R/R AML, remaining on track for a comprehensive data readout in Q1 2027.

ClaimPhathom Pharmaceuticals has initiated a registrational Phase 3 study (pHalcon-NERD-302) to evaluate as-needed VOQUEZNA (vonoprazan) 10 mg for adults with Non-Erosive GERD, with topline results expected in Q1 2028.

ClaimCellectar Biosciences' iopofosine I 131 demonstrated a 79.2% Major Response Rate and 87.5% Overall Response Rate with a Duration of Response exceeding 16 months in BTK inhibitor-refractory/resistant Waldenström Macroglobulinemia patients from a Phase 2 subset analysis.

ClaimKodiak Sciences announced it will present topline results from its DAYBREAK pivotal Phase 3 study of Zenkuda and KSI-501 for wet age-related macular degeneration on September 28, 2026.

ClaimZenkuda (tarcocimab tedromer) met its primary endpoint in the Phase 3 DAYBREAK study for wet age-related macular degeneration, demonstrating non-inferiority in vision gains compared to aflibercept at year one, with a majority of patients on a 6-month dosing interval.

ClaimInnovent Biologics has expanded its global Phase III MarsLight-11 trial for IBI363 to include non-squamous non-small cell lung cancer patients.

ClaimMirum Pharmaceuticals will host an investor call on September 28, 2026, to share topline results from its Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus.

ClaimMirum Pharmaceuticals announced that its investigational drug, brelovitug, met the primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta virus, demonstrating significant virologic response and ALT normalization at Week 24.

ClaimAkeso's ivonescimab demonstrated positive overall survival results in the Phase III HARMONi-GI1 trial for first-line advanced biliary tract cancer, leading to its selection as a Late-Breaking Abstract at ESMO 2026.

ClaimAkeso, Inc. has enrolled the first patient in its global Phase III COMPASSION-37 trial, evaluating cadonilimab plus chemotherapy as a first-line treatment for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

ClaimAdicet Bio's allogeneic gamma delta CAR-T therapy, prula-cel, demonstrated promising efficacy and a favorable safety profile in an early-stage trial for lupus nephritis patients.

ClaimMilestone Pharmaceuticals has enrolled the first Canadian participant in its ReVeRA-301 Phase 3 pivotal trial, evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR).

ClaimClywedog Therapeutics' investigational oral drug balomenib demonstrated sustained improvements in glycaemic control and a favorable safety profile in adults with type 2 diabetes in a Phase Ib trial.

ClaimMerck's investigational drug, remigromig, demonstrated non-inferiority to ranibizumab in improving best-corrected visual acuity in adults with diabetic macular edema in the pivotal Phase 2b/3 BRUNELLO study.

ClaimOptimi Health Corp. has completed the production and quality release of a cGMP batch of 5mg naturally derived psilocybin capsules to supply both its Health Canada-approved Phase 2 clinical trial for major depressive disorder and commercial customers in Australia for treatment-resistant depression.

ClaimPridCor Therapeutics has initiated the enrollment process for its Phase 2 SHIELD study, evaluating a combination antiviral regimen for adults with Long COVID.

ClaimAcadia Pharmaceuticals' remlifanserin narrowly missed its primary endpoint in a Phase 2 trial for Alzheimer's disease psychosis but will advance to Phase 3 based on secondary endpoint data and a modified dosage strategy.

ClaimKyverna Therapeutics announced positive one-year topline data for miv-cel in Stiff Person Syndrome and longer-term follow-up data in generalized myasthenia gravis, demonstrating durable clinical responses and a favorable safety profile.

ClaimRoche and Ionis Pharmaceuticals' experimental drug sefaxersen met its primary endpoint in a Phase 3 clinical trial for IgA nephropathy, showing statistically significant and clinically meaningful improvements in urine protein.

ClaimUlefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS.

ClaimIonis Pharmaceuticals and Roche announced positive interim results from the Phase 3 IMAgINATION study, showing sefaxersen significantly reduced proteinuria in adults with primary IgA nephropathy.

ClaimActimed Therapeutics has successfully completed patient recruitment for its PROACT Phase 2a study evaluating S-pindolol benzoate in obese adults receiving and discontinuing semaglutide therapy.

ClaimNew results from the Phase 2b COPERNICUS study demonstrate consistently low rates of key treatment-related events and treatment discontinuation with subcutaneous RYBREVANT FASPRO plus LAZCLUZE and prophylactic strategies in previously untreated advanced EGFR-mutated NSCLC.

ClaimCAPLYTA® (lumateperone) demonstrated a statistically significant and rapid reduction in manic symptoms versus placebo in a pivotal Phase 3 study for bipolar I disorder.

ClaimPycnogenol®, a standardized French maritime pine bark extract, has demonstrated clinically backed cognitive support across multiple generations, including children with ADHD, students, working professionals, and older adults with moderate cognitive decline.

ClaimViking Therapeutics' VK2735 demonstrated superior weight loss maintenance with monthly and every-other-week dosing regimens and an encouraging safety profile in a maintenance study for obesity.

ClaimCelldex's barzolvolimab met primary and all key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria, demonstrating rapid, profound, and sustained efficacy with a favorable safety profile.

ClaimCaplyta (lumateperone) met its primary and a key secondary endpoint in a Phase III trial for the treatment of manic episodes in adults with bipolar I disorder, demonstrating significant and rapid symptom reduction.

ClaimMarlaina Goedel achieved two years of insulin independence following a pancreatic islet cell transplantation with Eledon Pharmaceutical Inc.'s investigational anti-rejection drug, tegoprubart.

ClaimEli Lilly presented early-stage Phase 1 data for its dual GLP-1/GIP receptor agonist, brenipatide, supporting its potential in major depressive disorder and alcohol use disorder, with Phase 3 trials currently underway.